Effect of goserelin combined with medroxyprogesteron acetate in treatment of endometriosis and its impact on serum growth factor and tumor marker levels
[Objective]To explore and analyze the effect of goserelin combined with medroxyprogesteron acetate on the treatment of endometriosis and its impact on serum growth factor and tumor marker levels.[Methods]Seventy-six patients with endometriosis admitted to Rushan city Hospital of Traditional Chinese Medicine from June 2021 to June 2023 were randomly divided into a control group(medroxyprogesteron acetate)and an observation group(goserelin combined with medroxyprogesteron acetate),with 38 cases in each group.The treatment outcomes of the two groups were compared and analyzed.[Results]Compared with the control group,the therapeutic effect of the observation group was significantly higher(P＜0.05).After treatment,the observation group showed significantly lower levels of luteinizing hormone(LH),estradiol(E2),and follicle stimulating hormone(FSH)compared with the control group(P＜0.05);serum tumor necrosis factor-α(TNF-α),matrix metalloproteinase-9(MMP-9)and epithelial neutrophil activating peptide 78(ENA-78)in the observation group were significantly lower than those in the control group(P＜0.05);the levels of vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125)were significantly lower in the observation group than in the control group(P＜0.05).[Conclusion]The combination of goserelin and medroxyprogesteron acetate can improve the therapeutic effect for endometriosis,promote the improvement of sexual hormones and inflammatory indicators in patients,and also regulate the levels of serum growth factors and tumor markers.It is worth promoting.
万方数据
维普
